Prevalencia de consumo riesgoso y dañino de alcohol en derechohabientes del Instituto Mexicano del Seguro Social

Objetivo. Medir la prevalencia de consumo riesgoso y dañino de alcohol en la población amparada por el Instituto Mexicano del Seguro Social (IMSS). Material y métodos. En un estudio transversal se entrevistaron 45 117 derechohabientes del IMSS, en las 36 delegaciones del país. Se aplicó un cuestionario estructurado y autoaplicable a cada sujeto usando el instrumento de tamizaje AUDIT (Alcohol Use Disorder Identification Test), el cual consta de 10 preguntas. Las tres primeras se relacionan con la cantidad y frecuencia del consumo de alcohol, las tres siguientes evalúan la dependencia y las cuatro últimas se refieren a problemas causados por el alcohol. Cada pregunta consta de tres a cinco opciones, a las que se les asignan valores progresivos de cero a cuatro. Se estimó la prevalencia de consumo, con intervalos de confianza al 95% (IC 95%). Resultados. La prevalencia de consumo problema de alcohol (riesgoso y dañino) fue de 12.8% (IC 95% 12.5-13.2). El consumo fue mayor en hombres (22.2%; IC 95% 21.7-22.8) que en mujeres (3.4%; IC 95% 3.1-3.6). En los hombres se observó un efecto de edad, mientras que en las mujeres el consumo por edad fue más homogéneo. En ambos grupos el consumo fue más importante en la edad productiva. Conclusiones. La prevalencia de consumo de alcohol que constituye un problema para la salud, es elevada en la población derechohabiente del IMSS. Es necesario desarrollar políticas y programas de salud específicos, para disminuir este grave problema

Impact of Adding a Rapid PCR-Based Blood Culture Identification Panel to the Antimicrobial Stewardship Program of Patients with Febrile Neutropenia in a Peruvian Referral Hospital

The addition of Biofire® FilmArray® Blood Culture Identification panel 2 (BCID2) to the antimicrobial stewardship program (ASP) could improve outcomes in bloodstream infections (BSI) of patients with febrile neutropenia (FN). A pre- and post-quasi-experimental single-center study was conducted at a reference hospital in Peru. Three groups were considered: patients with BSI before ASP intervention (control group), patients with BSI after ASP intervention (group 1), and patients with BSI after ASP intervention plus BCID2 PCR Panel implementation (group 2). Overall, 93 patients were identified (32 control, 30 group 1, 31 group 2). The median time to effective therapy was significantly shorter in group 2 compared to group 1 and control group, respectively (3.75 vs. 10 h, p = 0.004; 3.75 vs. 19 h, p p < 0.001). In addition to the lack of local studies documenting the microbiological profile of FN episodes, adding syndromic panels-based testing could allow for the consolidation of ASP strategies

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective